Biocon Ltd - BIOCON Share Price

Sector: Pharmaceuticals | ISIN: INE376G01013
₹ 280.15 (3.32%) icon23 Apr, 2024, 12:00:00 AM
Open
₹ 275.00
Prev. Close
₹ 271.15
Turnover(lac)
₹ 0.29
Day's High
₹ 281.00
Day's Low
₹ 271.30
52 Wk High
₹ 307.10
52 Wk Low
₹ 217.50
Book Value
₹ 91.79
Face Value
₹ 5.00
Mkt. Cap (Cr.)
₹ 33,634.81
P/E
0.00
EPS
0.40
Div. Yield
0.54

Biocon Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 4/23/2024 12:00:00 AM

    ₹ 280.15 9.00 3.32
  • Open
  • ₹ 275
  • Prev. Close
  • ₹ 271.15
  • Turnover(Lac.)
  • ₹ 0
  • Day's High
  • ₹ 281
  • Day's Low
  • ₹ 271.3
  • 52 Week's High
  • ₹ 307.1
  • 52 Week's Low
  • ₹ 217.5
  • Book Value
  • ₹ 91.79
  • Face Value
  • ₹ 5
  • Mkt Cap (₹ Cr.)
  • 33,634.81
  • P/E
  • 0
  • EPS
  • 0.4
  • Divi. Yield
  • 0.54

Biocon Ltd Corporate Actions

10 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

10 Jan , 2024

12:00 AM

09 Oct , 2023

12:00 AM

09 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

23 May , 2023

12:00 AM

AGM

Announcement date: 23 May , 2023

View Details

21 Jul , 2023

12:00 AM

21 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

23 May , 2023

12:00 AM

Dividend

Dividend amount: 1.5
Announcement date: 23 May , 2023

View Details

20 Apr , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

20 Apr , 2023

12:00 AM

23 Apr , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

No Record Found


Biocon Ltd News and Update

Image not found

The application for Liraglutide was filed by Biocon through its European partner, Zentiva.

Image not found

Biocon Biologics slips ~6% after CFO Indranil Sen steps down

Indranil Sen has resigned to seek possibilities outside of the organisation.

  • 15 Mar, 2024 |
  • 2:28 PM
Image not found

Eris Lifesciences purchases Biocon Biologics’ domestic brand formulations biz

As part of the agreement, around 430 people from the company are scheduled to migrate to Eris.

  • 15 Mar, 2024 |
  • 11:38 AM
Image not found

Biocon soars on US market entry deal with J&J

Under the terms of the agreement, the product may be introduced in the US in February 2025 after receiving FDA approval.

  • 01 Mar, 2024 |
  • 11:31 AM

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Biocon Ltd SHAREHOLDING SNAPSHOT
24 April , 2024 | 07:48 AM

PROMOTER - TOTAL60.64%

Indian: 40.36%

Foreign: 20.2767%

NON-PROMOTER - TOTAL 39.05%

Institutions: 19.31%

Non-Institutions: 19.73%

CUSTODIES - 0.32%

Custodies: 0.32%

See More Details
ad IconAd Image

Biocon Ltd FINANCIALS

Biocon Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Biocon Ltd

  • Kiran Mazumdar Shaw
  • Chairperson
  • Ravi Mazumdar
  • Director
  • Vijay Kumar Kuchroo
  • Independent Director
  • M Damodaran
  • Independent Director
  • Bobby Parikh
  • Independent Director
  • Mayank Verma
  • Company Sec. & Compli. Officer
  • SIDDHARTH MITTAL
  • Managing Director & CEO
  • Eric Vivek Mazumdar
  • Director
  • Naina Lal Kidwai
  • Independent Director
  • Peter John Bains
  • Independent Director

Summary

Biocon Limited is Indias largest and fully-integrated, innovation-led biopharmaceutical company. The Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in the year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw. Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind. In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International. Also in the same year, the company had received US funding for proprietary technologies. After a year, in 1990, Biocon had scaled up its in-house research programme, based on a proprietary solid substrate fermentation technology, from pilot to plant level. Biocons R&D and manufacturing facilities received ISO 9001 certification from RWTUV, Germany during the period of 1993. In the year 1994, the company had established the Syngene International Pvt. Ltd. as a Custom research Company (CRC) to address the growing need for outsourced R&D in the pharmaceutical sector. The commercial success of Biocons proprietary fermentation plant leads to a 3-fold expansion during the year 1996 and also in the same year, the company had leveraged its technology platform to enter biopharmaceuticals and statins. Biocon had spearheads initiatives in human healthcare in the year 1997 through a dedicated manufacturing... Read More


Reports by Biocon Ltd


Reports by Biocon Ltd

Company FAQ

What is the Market Cap of Biocon?

Is Biocon a govt company?

What is the promoter shareholding in Biocon?

Is Biocon profitable?

Who is the Managing Director of Biocon Limited?

What is the ROE of Biocon Limited?

What is the debt-to-equity ratio of Biocon Limited?

What is the stock price CAGR of Biocon Limited?

How many times has Biocon Limited given dividends since 2004?

Is it a good time to invest in Biocon Limited?

What is the PB ratio of Biocon?

Which are the key peers to Biocon?

How can I quickly analyze Biocon stock?

Who's the owner of Biocon?

What is the 52 Week High and Low of Biocon?

What is the PE and PB ratio of Biocon?

What is the Share Price of Biocon?

How to Buy Biocon Share?